These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18992382)

  • 1. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis.
    Rogoza RM; Ferko N; Bentley J; Meijer CJ; Berkhof J; Wang KL; Downs L; Smith JS; Franco EL
    Vaccine; 2008 Sep; 26 Suppl 5():F46-58. PubMed ID: 18992382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ
    Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
    Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
    Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.
    Suárez E; Smith JS; Bosch FX; Nieminen P; Chen CJ; Torvinen S; Demarteau N; Standaert B
    Vaccine; 2008 Sep; 26 Suppl 5():F29-45. PubMed ID: 18992380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
    Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
    BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
    Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
    BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of vaccination against HPV in Israel.
    Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
    Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer.
    Franco EL; Bosch FX; Cuzick J; Schiller JT; Garnett GP; Meheus A; Wright TC
    Vaccine; 2006 Aug; 24 Suppl 3():S3/242-9. PubMed ID: 16950013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis: an essential tool to inform public health policy in cervical cancer prevention.
    Franco EL; Drummond MF
    Vaccine; 2008 Sep; 26 Suppl 5():F1-2. PubMed ID: 18992378
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination.
    Debicki D; Ferko N; Demarteau N; Gallivan S; Bauch C; Anonychuk A; Mantovani L; Capri S; Chou CY; Standaert B; Annemans L
    Vaccine; 2008 Sep; 26 Suppl 5():F16-28. PubMed ID: 18992379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.
    Garnett GP; Kim JJ; French K; Goldie SJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/178-86. PubMed ID: 16950005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of HPV vaccines: not just cervical cancer.
    Myers ER
    Am J Obstet Gynecol; 2008 May; 198(5):487-8. PubMed ID: 18455522
    [No Abstract]   [Full Text] [Related]  

  • 20. Recommendations for cervical cancer prevention in Latin America and the Caribbean.
    Muñoz N; Franco EL; Herrero R; Andrus JK; de Quadros C; Goldie SJ; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 11():L96-L107. PubMed ID: 18945407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.